SG11202112254YA - Methods of treating cancer using chk1 inhibitors - Google Patents

Methods of treating cancer using chk1 inhibitors

Info

Publication number
SG11202112254YA
SG11202112254YA SG11202112254YA SG11202112254YA SG11202112254YA SG 11202112254Y A SG11202112254Y A SG 11202112254YA SG 11202112254Y A SG11202112254Y A SG 11202112254YA SG 11202112254Y A SG11202112254Y A SG 11202112254YA SG 11202112254Y A SG11202112254Y A SG 11202112254YA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
chk1 inhibitors
chk1
inhibitors
Prior art date
Application number
SG11202112254YA
Inventor
Christian Hassig
Bryan Strouse
Ryan Hansen
Kenna Anderes
Snezana Milutinovic
Angie You
Barbara Klencke
Mark Kowalski
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Publication of SG11202112254YA publication Critical patent/SG11202112254YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202112254YA 2019-05-14 2020-05-13 Methods of treating cancer using chk1 inhibitors SG11202112254YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847810P 2019-05-14 2019-05-14
US201962855910P 2019-05-31 2019-05-31
PCT/US2020/032722 WO2020232154A2 (en) 2019-05-14 2020-05-13 Methods of treating cancer using chk1 inhibitors

Publications (1)

Publication Number Publication Date
SG11202112254YA true SG11202112254YA (en) 2021-12-30

Family

ID=73289782

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112254YA SG11202112254YA (en) 2019-05-14 2020-05-13 Methods of treating cancer using chk1 inhibitors

Country Status (11)

Country Link
US (1) US20220226338A1 (en)
EP (1) EP3969623A4 (en)
JP (1) JP2022532597A (en)
KR (1) KR20220066005A (en)
CN (1) CN114072526A (en)
AU (1) AU2020274164A1 (en)
CA (1) CA3140123A1 (en)
IL (1) IL288003A (en)
MX (1) MX2021013905A (en)
SG (1) SG11202112254YA (en)
WO (1) WO2020232154A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024009946A1 (en) * 2022-07-08 2024-01-11 国立大学法人東海国立大学機構 Method for testing effectiveness of parp inhibitor against ovarian cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793882A4 (en) * 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
EP2855448B1 (en) * 2012-05-15 2017-02-08 Cancer Research Technology Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EP3548897A4 (en) * 2016-12-01 2020-08-12 Nantomics, LLC Tumor antigenicity processing and presentation
KR102645511B1 (en) * 2017-04-10 2024-03-08 시에라 온코로지 엘엘씨 CHK1(SRA737)/PARPi combination method to inhibit tumor growth
WO2018191299A1 (en) * 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
EP3631444A4 (en) * 2017-06-01 2021-06-09 Sierra Oncology, Inc. Biomarkers and patient selection strategies
CN112469391A (en) * 2018-02-26 2021-03-09 塞拉肿瘤学公司 Methods of treating cancer comprising CHK1 inhibitors
WO2020198510A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors

Also Published As

Publication number Publication date
IL288003A (en) 2022-01-01
CA3140123A1 (en) 2020-11-19
MX2021013905A (en) 2022-05-18
KR20220066005A (en) 2022-05-23
EP3969623A4 (en) 2023-06-14
CN114072526A (en) 2022-02-18
AU2020274164A1 (en) 2021-11-25
JP2022532597A (en) 2022-07-15
WO2020232154A2 (en) 2020-11-19
EP3969623A2 (en) 2022-03-23
WO2020232154A3 (en) 2020-12-24
US20220226338A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
IL277665A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL288395A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP3464643A4 (en) Use of ezh2 inhibitors for treating cancer
IL288707A (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
IL286297A (en) Methods of treating minimal residual cancer
SG11202010793UA (en) Methods of treating cancer
IL279591A (en) Methods of treating cancer using combination therapy
SG11202107017TA (en) Methods of treating cancer
EP3630080A4 (en) Use of ezh2 inhibitors for treating cancer
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
EP3758678A4 (en) Methods of treatment of cancer comprising chk1 inhibitors
IL281600A (en) Methods of treating cancer
EP3946419A4 (en) Methods of treating cancer with chk1 inhibitors
IL277981A (en) Methods of treating cancer
IL288003A (en) Methods of treating cancer using chk1 inhibitors
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors
IL268722A (en) Methods of treating cancer with farnesyltransferase inhibitors
IL289811A (en) Method of treating cancer
IL282738A (en) Methods of treating cancer with farnesyltransferase inhibitors
IL290213A (en) Methods of treating multifocal cancer
EP4072561A4 (en) Methods of treating cancer
IL272473A (en) Methods of treating cancer with farnesyltransferase inhibitors
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer